Alimera Sciences (ALIM) 5.19 $ALIM
Alimera Sciences Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 3:05PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31, 2014.
Alimera Sciences To Release First Quarter 2014 Results
PR Newswire - Thu May 01, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter of fiscal year 2014 financial results after the market close on Thursday, May 8, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET.
pSivida to commercialise ILUVIEN for DME in Australia/New Zealand through STA
M2 - Tue Apr 29, 5:13AM CDT
Drug delivery company pSivida (NasdaqGM
SDV) (ASXVA.AX) disclosed on Monday the launch of an exclusive agreement for the distribution of ILUVIEN for the treatment of diabetic macular edema (DME) in Australia and New Zealand.
pSivida Reports Australia/New Zealand Distribution Agreement for ILUVIEN(R) for DME
Business Wire - Mon Apr 28, 6:06AM CDT
pSivida Corp. (NASDAQSDV) (ASXVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN(R) for the treatment of diabetic macular edema (DME). Under the agreement, STA also will handle all regulatory and commercial activities for ILUVIEN in those countries.
Alimera Sciences Signs Specialised Therapeutics Australia (STA) As Exclusive ILUVIEN® Distributor For Australia, New Zealand
PR Newswire - Mon Apr 28, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive five-year agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN®, Alimera's sustained release intravitreal injection for the treatment of diabetic macular edema. Under the terms of this agreement, STA also will handle all regulatory and commercial activities for ILUVIEN in those countries.
Specialised Therapeutics Australia To License New Drug - Iluvien(R) - To Improve Vision in Patients With Diabetes-induced Vision Loss
PR Newswire - Mon Apr 28, 6:00AM CDT
Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences (NASDAQ: ALIM).
Alimera Sciences awarded USD35m debt facility for the commercialisation of ILUVIEN
M2 - Mon Apr 28, 5:40AM CDT
Biopharmaceutical company Alimera Sciences (NasdaqGM:ALIM) disclosed on Friday the launch of up to USD35m Loan and Security Agreement with Hercules Technology Growth Capital (NYSE:HTGC).
Alimera Sciences Secures $35 Million Debt Facility
PR Newswire - Fri Apr 25, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited (Limited), has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules) for a term loan in the principal amount of up to $35 million. Under the agreement, Hercules is advancing $10 million to Limited and will advance the remaining $25 million in the event the U.S. Food and Drug Administration (FDA) approves ILUVIEN® on or before October 31, 2014 and certain other conditions are satisfied.
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
pSivida announces 26 September 2014 as the PDUFA date for ILUVIEN
M2 - Tue Apr 15, 5:51AM CDT
Drug delivery company pSivida (NasdaqGMSDV) (ASXVA.AX) declared on Monday that the US Food and Drug Administration (FDA) has set Prescription Drug User Fee Act (PDUFA) goal date of 26 September 2014 for ILUVIEN.
Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia
Leo Sun, The Motley Fool - Motley Fool - Mon Apr 14, 8:13AM CDT
Let's take a quick look at three biotech stocks -- Lexicon Pharmaceuticals , Alimera Sciences , and Akebia Therapeutics -- which could all be lifted by positive headlines this Monday morning . Lexicon soars on positive top-line results for...
pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN(R)
Business Wire - Mon Apr 14, 6:04AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN(R) following the recent resubmission of the New Drug Application (NDA) by pSivida's licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA's October 2013 complete response letter.
Alimera Sciences Announces New PDUFA Date For ILUVIEN®
PR Newswire - Mon Apr 14, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN® has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the FDA's October 2013 letter and that a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 has been established.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 28, 7:21PM CDT
Cramer says the market needs both a China stimulus plan and positive U.S. employment numbers to sustain any gains.
pSivida Announces Resubmission of New Drug Application for ILUVIEN(R)
Business Wire - Thu Mar 27, 6:05AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe.
Alimera Sciences Announces Resubmission Of ILUVIEN® New Drug Application To FDA
PR Newswire - Thu Mar 27, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA). At this time, Alimera awaits the FDA's acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date. Alimera intends to provide that information when it becomes available.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference
PR Newswire - Fri Feb 28, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera", a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:00 A.M. ET in Boston, MA.
Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:07PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results
PR Newswire - Thu Feb 20, 3:05PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera", a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET.
Alimera Sciences Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 08, 3:05PM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31, 2014.
Alimera Sciences To Release First Quarter 2014 Results
PR Newswire - Thu May 01, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter of fiscal year 2014 financial results after the market close on Thursday, May 8, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. pSivida to commercialise ILUVIEN for DME in Australia/New Zealand through STA
M2 - Tue Apr 29, 5:13AM CDT
Drug delivery company pSivida (NasdaqGM
SDV) (ASXVA.AX) disclosed on Monday the launch of an exclusive agreement for the distribution of ILUVIEN for the treatment of diabetic macular edema (DME) in Australia and New Zealand. pSivida Reports Australia/New Zealand Distribution Agreement for ILUVIEN(R) for DME
Business Wire - Mon Apr 28, 6:06AM CDT
pSivida Corp. (NASDAQ
SDV) (ASXVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN(R) for the treatment of diabetic macular edema (DME). Under the agreement, STA also will handle all regulatory and commercial activities for ILUVIEN in those countries. Alimera Sciences Signs Specialised Therapeutics Australia (STA) As Exclusive ILUVIEN® Distributor For Australia, New Zealand
PR Newswire - Mon Apr 28, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive five-year agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN®, Alimera's sustained release intravitreal injection for the treatment of diabetic macular edema. Under the terms of this agreement, STA also will handle all regulatory and commercial activities for ILUVIEN in those countries.
Specialised Therapeutics Australia To License New Drug - Iluvien(R) - To Improve Vision in Patients With Diabetes-induced Vision Loss
PR Newswire - Mon Apr 28, 6:00AM CDT
Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Alimera Sciences (NASDAQ: ALIM).
Alimera Sciences awarded USD35m debt facility for the commercialisation of ILUVIEN
M2 - Mon Apr 28, 5:40AM CDT
Biopharmaceutical company Alimera Sciences (NasdaqGM:ALIM) disclosed on Friday the launch of up to USD35m Loan and Security Agreement with Hercules Technology Growth Capital (NYSE:HTGC).
Alimera Sciences Secures $35 Million Debt Facility
PR Newswire - Fri Apr 25, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited (Limited), has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules) for a term loan in the principal amount of up to $35 million. Under the agreement, Hercules is advancing $10 million to Limited and will advance the remaining $25 million in the event the U.S. Food and Drug Administration (FDA) approves ILUVIEN® on or before October 31, 2014 and certain other conditions are satisfied.
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:45PM CDT
The FDA accepted Alimera Sciences' re-submitted NDA for Iluvien. PDUFA date for Iluvien is now set for Sep 26, 2014.
pSivida announces 26 September 2014 as the PDUFA date for ILUVIEN
M2 - Tue Apr 15, 5:51AM CDT
Drug delivery company pSivida (NasdaqGM
SDV) (ASXVA.AX) declared on Monday that the US Food and Drug Administration (FDA) has set Prescription Drug User Fee Act (PDUFA) goal date of 26 September 2014 for ILUVIEN. Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia
Leo Sun, The Motley Fool - Motley Fool - Mon Apr 14, 8:13AM CDT
Let's take a quick look at three biotech stocks -- Lexicon Pharmaceuticals , Alimera Sciences , and Akebia Therapeutics -- which could all be lifted by positive headlines this Monday morning . Lexicon soars on positive top-line results for...
pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN(R)
Business Wire - Mon Apr 14, 6:04AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN(R) following the recent resubmission of the New Drug Application (NDA) by pSivida's licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA's October 2013 complete response letter.
Alimera Sciences Announces New PDUFA Date For ILUVIEN®
PR Newswire - Mon Apr 14, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN® has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the FDA's October 2013 letter and that a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 has been established.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 28, 7:21PM CDT
Cramer says the market needs both a China stimulus plan and positive U.S. employment numbers to sustain any gains.
pSivida Announces Resubmission of New Drug Application for ILUVIEN(R)
Business Wire - Thu Mar 27, 6:05AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe.
Alimera Sciences Announces Resubmission Of ILUVIEN® New Drug Application To FDA
PR Newswire - Thu Mar 27, 6:00AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA). At this time, Alimera awaits the FDA's acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date. Alimera intends to provide that information when it becomes available.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference
PR Newswire - Fri Feb 28, 6:30AM CST
Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"
, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:00 A.M. ET in Boston, MA. Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:07PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013.
Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results
PR Newswire - Thu Feb 20, 3:05PM CST
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"
, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. 
